Company: MIRA
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001493152-25-026444
Chunk: 1

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-12-05
Form: 424B5
Chunk 1
---
.

Pursuant to General Instruction I.B.6, as of the date hereof, we currently may offer and sell Common Stock having an aggregate offering price of up to $15,241,591 under the Sales Agreement, which amount is in addition to the Common Stock that we have sold to date in accordance with the Sales Agreement under the Prior Prospectus. If our public float increases such that we may sell additional amounts under the Sales Agreement and the Registration Statement of which this Prospectus Supplement and the Prior Prospectus are a part, we will file another prospectus supplement prior to making additional sales. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding one-third of the aggregate market value of our Common Stock held by non-affiliates in any 12 calendar month period, so long as the aggregate market value of our outstanding Common Stock held by non-affiliates remains below $75 million. As of the date hereof, we have offered $7,034,658 shares of Common Stock pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof.

Our Common Stock is listed on the Nasdaq Capital Market under the symbol “MIRA.” On December 4, 2025, the last reported sale price of our Common Stock on the Nasdaq Capital Market was $1.48 per share.

We are an “emerging growth company” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”) and a smaller reporting company as defined under Rule 405 of the Securities Act, and as such, we have elected to comply with certain reduced public company reporting requirements. See “Prospectus Summary— Implications of Being a Smaller Reporting Company and Emerging Growth Company” on page S-5 of the Prior Prospectus.

Investing in the offered securities involves a high degree of risk. Before buying any shares, you should read the discussion of material risks of investing in our Common Stock in “Risk Factors” beginning on page S-2 of the Prior Prospectus, and in our most recent Annual Report on Form 10-K and in the risks discussed under similar headings in the documents incorporated by reference in this Prospectus Supplement and the Prior Prospectus, as they may be amended, updated or modified periodically in our reports filed with the Securities and Exchange Commission.

NEITHER THE